Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TMS Co., Ltd. ( (JP:4891) ) just unveiled an announcement.
TMS Co., Ltd. announced that Dr. Edmond Chen will present findings on TMS-007 (JX10), a novel thrombolytic with anti-inflammatory properties, at the International Stroke Conference 2025. The presentation will discuss its efficacy in treating acute lacunar infarct, as demonstrated in a Phase 2a study. This development highlights TMS’s commitment to advancing stroke treatment and could strengthen its position in the biopharmaceutical industry.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines for serious diseases with high unmet medical needs. Their pipeline, based on small molecule compounds derived from a fungus, includes treatments for acute ischemic stroke, hypertension, acute kidney injury, and spinal cord injury. They partner with leading academic institutions in Japan to connect academic discoveries with the global pharmaceutical market.
YTD Price Performance: -5.05%
Average Trading Volume: 555,340
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen8.35B
For an in-depth examination of 4891 stock, go to TipRanks’ Stock Analysis page.